No abstract

Carrier and prenatal diagnosis based on the identification of the gene defect (direct diagnosis) increases the proportion of haemophilia B families that can be offered precise genetic counselling from the 50-60% attainable by DNA markers, to 100% and they also provide information on the molecular biology of the disease. We propose that in order to maximize the practical and scientific benefits of direct diagnosis the gene defect of complete (possibly national) populations of patients should be characterized and the information stored in appropriate confidential databases. We demonstrate the feasibility of such a strategy by characterizing the mutations of all the patients registered with the Malmö haemophilia centre. These patients (44 male and 1 female) are from 45 unrelated families and 24 (53%) have negative family history. The 25 patients with similar reduction of factor IX:C and factor IX:Ag (24 male + 1 female) have: two gross deletions, three frameshifts, four translation stops, six mutations expected to affect pre-mRNA splicing and 10 amino acid substitutions. The six patients with greater reduction of factor IX:C than factor IX:Ag and the seven with reduced IX:C and normal IX:Ag have only amino acid substitutions. Patients with inhibitors have: one complete deletion, one frameshift and three translation stops. One patient has both a translation stop and a functionally neutral amino acid substitution (His257----Tyr). Characterization of the factor IX mutation was successful in every case, usually entailed 4 person-days work, and has led to the identification of 12 amino acid residues essential for the factor IX structure and function.

SummaryThe Simplate II-R and the Simplate Paediatric, are two new Simplate bleeding time devices with retractable blades. In this study we compared the Simplate II-R with the Simplate II bleeding time and found a good correlation when performed by the same technician both in 30 healthy volunteers and in 7 patients with prolonged bleeding time. The same normal ranges may be applied for the Simplate II-R as for the Simplate II bleeding time. The Simplate II-R bleeding time was highly reproducible in healthy volunteers when performed by the same technician. We found no correlation between age and bleeding time, and no significant difference in bleeding time between males and females.We performed the Simplate Paediatric bleeding time test and calculated the normal ranges in 84 healthy children in 4 age groups: 3 days, 3 months, 1 year and 3–6 years of age. The Simplate Paediatric bleeding times were shorter in the children than the Simplate II-R bleeding times in the adults. We found no significant correlation between bleeding time and the inverse platelet count, and no significant difference in bleeding time between boys and girls. The retractable blades in the Simplate II-R and the Simplate Paediatric reduce the risk of accidental cuts. Both devices yield reproducible bleeding time measurements and can be used instead of older Simplate variants.

Mutation rates for X-linked recessive diseases have so far been estimated indirectly by postulating an equilibrium between the loss of defective genes caused by the low reproductive fitness of affected males and the gain resulting from new mutations. Here, for the first time, we directly estimate both the overall and sex-specific mutation rates for haemophilia B by detecting the gene defect of the families registered at the Malmö Haemophilia Centre. These represent a complete sample of the Swedish haemophilia B population (45 out of 77 pedigrees) and contain 23 families with a single affected male. Fifteen of these males had mothers available for study, and of these mothers, 13 had parents available for study. We show that 3 of the above patients and 10 of their mothers carry new mutations, and by extrapolation calculate that 8 males and 98 females should carry new haemophilia B mutations in the Swedish population (8.52 x 10(6) individuals). This leads to the following estimate of the mutation rates: overall mu = 4.1 x 10(-6); male specific nu = 2.1 x 10(-5); and female specific mu = 1.9 x 10(-6). The ratio of such male to female specific mutation rates is thus nu/mu = 11.